Meeting
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.
Authors
Amy E. Chang
University of Michigan, Ann Arbor, MI
Amy E. Chang , David Bing Zhen , Marc Radke , Kelsey K. Baker , Andrew L. Coveler , Kit Man Wong , Venu Gopal Pillarisetty , Mary Weber Redman , Elizabeth Swisher , E. Gabriela Chiorean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 732)
Abstract #
732
Poster Bd #
L21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
First Author: Qiuxiang Ou
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prevalence of germline mutations and homologous recombination deficiency (HRD) in a real-world biliary tract cancer (BTC) cohort.
First Author: Robin Kate Kelley